The current data suggests that AMI exerts its neuroprotective effects against tauopathy through modulation of colonic ASM activity, associated gut ceramide levels, GM, colonic inflammation and membrane integrity through bidirectional gut-brain axis leading to distinct reduction in P-tau in hippocampus mainly by upregulation of PP2A which regulates tau aggregation and improves neurogenesis. The gene discussed is MAPT; the disease is tauopathy.